• Profile
Close

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

Gynecologic Oncology May 24, 2018

Konstantinopoulos PA, et al. - Single-agent cabozantinib was evaluated for its efficacy and tolerability in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. Researchers recruited patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0–2 to receive cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity. They noted no objective responses, however, 3 of 13 patients exhibited progression-free survival ≥ 6 months. Cabozantinib thus demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma. Thromboembolism, nausea, vomiting, fatigue, dyspnea, dehydration were the grade ≥3 AEs encountered.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay